JCAR 017

Drug Profile

JCAR 017

Alternative Names: anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; EGFRt-4-1BB-modified-CAR-CD8+-and-CD4+-T-lymphocytes-Juno-Therapeutics; Gene modified autologous T cells; JCAR017

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Developer Celgene Corporation; Juno Therapeutics; Seattle Children's Hospital
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leukaemia
  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Nov 2017 Juno Therapeutics plans the phase I/II TRANSCEND-CLL-004 trial in Chronic lymphocytic leukaemia or Small lymphocytic lymphoma (Second-line therapy or greater, Monotherapy, Combination therapy) in USA (NCT03331198)
  • 01 Nov 2017 JCAR 017 receives Regenerative Medicine Advanced Therapy (RMAT) designation for Non-Hodgkin's lymphoma, including Diffuse large B cell lymphoma, before November 2017
  • 01 Nov 2017 Juno Therapeutics intends to file BLA for JCAR 017 for the treatment of patients with Non-Hodgkin's lymphoma in USA in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top